Midlife may be the critical window for identifying metabolic dysfunction before progression to T2D. Join Dr Lee Kaplan, Dr Sarah Jarvis, Dr Arun Sanyal and Dr Sean Wharton ahead of the #EASD2026 congress to explore the links between visceral adipose tissue, liver health and glycaemic control. Midlife & T2D: A Critical Window in Metabolic Dysfunction 📅 21 September 2026 | 🕚 11:30 - 12:15 ET | 17:30 - 18:15 CEST | Live Q&A | Register free: radc.life/HBRx8yEk This programme has been sponsored by Boehringer Ingelheim. #VITALmetabolic #T2D #MetabolicHealth #LiverHealth #ObesityMedicine #Endocrinology

Advance your obesity management skills with this new CME-accredited course for primary care professionals. Join leading experts as they explore: ✅ Obesity as a chronic disease ✅ Latest obesity therapies ✅ Patient engagement strategies ✅ Treatment & referral pathways ✅ Integrated CKM care Learn from Prof Richard Hobbs, Dr Sean Wharton, Dr Lydia Alexander and Dr Helen Parretti and earn CME credits while enhancing your approach to obesity management in primary care. 🔗 ow.ly/uFF350Zzkwj This programme is supported by an unrestricted educational grant from Boehringer Ingelheim.

Are we missing metabolic disease by focusing on weight? The VITAL (Visceral adipose Tissue And the Liver) Initiative explores what sits beneath weight and why it matters. Over the coming months, VITAL will connect expert-led insights to build a clearer picture of metabolic health. Learn more about VITAL and the upcoming roundtables 🔗radc.life/mE4MkLEF This programme has been supported by an unrestricted educational grant from Boehringer Ingelheim. #VITALmetabolic #MetabolicHealth #Type2Diabetes #Cardiometabolic

Explore three dedicated specialty tracks examining obesity as a key driver of cardiometabolic, cardiovascular and kidney disease. Watch Here 🔗 ow.ly/kGOm50Zm3k1 Choose the track most relevant to your practice, covering: ✨ Early CKM risk ✨ Established CKM risk ✨ Progressive organ disease

What clinical markers can help identify patients who may benefit from earlier obesity treatment? In this session of 'Real-World Decisions: Implementing Disease-Modifying Obesity Therapy in Primary Care', Dr Lydia Alexander discusses the role of hsCRP and fasting insulin in recognising cardiometabolic risk and supporting earlier intervention strategies. Watch the full video series exploring practical approaches to obesity management in primary care: ow.ly/J7Wx50ZlyJy This programme is supported by an unrestricted educational grant from Boehringer Ingelheim.

💬 98.7% would recommend New Horizons in Obesity Management to a colleague ⭐ 98.2% rated the content very good or excellent 🔄 96.8% said it could change clinical practice Over three editions, New Horizons In Obesity Management has helped build a global community committed to examining obesity as a central driver of cardio-kidney-metabolic (CKM) disease and a core contributor to multimorbidity across organ systems We would like to thank our faculty, attendees and course directors Angela Fitch, Nikolaus Marx and Richard Hobbs for helping shape such a valued educational experience. New Horizons in Obesity Management 2026 is now available to watch on demand 👉 ow.ly/fAlS50ZjZ7m

Obesity is increasingly recognised as a chronic disease that lies at the centre of cardiometabolic, kidney and cardiovascular risk. In this on-demand symposium, Prof Richard Hobbs chairs an expert panel exploring disease-modifying obesity therapy in primary care 🔗 ow.ly/N3zm50Zjala The faculty discuss: ➡️ GLP-1 RAs ➡️ Dual incretins ➡️ Lifestyle integration ➡️ Monitoring and escalation This symposium is supported by an unrestricted educational grant from Boehringer Ingelheim.

New Horizons in Cardio Kidney Disease is now complete. What a great day! The operations team, Lauren Green, Calum Barlow, Mike Knight, David Ben-Harosh, Tom Green and Jennifer Thomas, would like to thank Course Directors Neha Pagidipati, Smeeta Sinha and Muthiah Vaduganathan, the faculty and everyone who joined us live, for making New Horizons in Cardio Kidney Disease 2026 a great success. We hope to see you again next year.

Leading international faculty are now actively debating real-world approaches to cardio-kidney disease management at New Horizons in Cardio Kidney Disease. Discussions are focused on how cardiology and nephrology perspectives can be aligned to improve consistency in risk stratification, treatment sequencing and multidisciplinary care delivery. Join the debate - ow.ly/373z50ZiIfl #CardioEd #MedEd #KidneyDisease #CardioKidney

📢 Taking place today | 14:10 CEST | 08:10 EDT Join Smeeta Sinha, Brendon Neuen, Alberto Ortiz and Navdeep Tangri for a symposium at New Horizons in Cardio Kidney Disease focused on the clinical use of eGFR slope in routine practice. Register here: ow.ly/f9i150ZixGz Key areas include: ✨ Distinguishing true progression from biological and measurement variability ✨ Linking eGFR trajectory to cardiovascular and renal risk ✨ Integrating slope with albuminuria, blood pressure and metabolic risk markers ✨ Using longitudinal data to support earlier intervention decisions This symposium is supported by an unrestricted educational grant from AstraZeneca. This session is not intended for UK based HCPs.

🚨 We’re About To Begin New Horizons in Cardio Kidney Disease 2026 goes live shortly. There’s still time to join. 🔗 Register now: ow.ly/SuQj50ZiyO2 Join leading international experts across cardiology, nephrology and primary care who are coming together to address the key challenges in cardio-kidney disease, from risk stratification to treatment optimisation in complex patients. The symposium 'Clinical Utility of eGFR Slope Across Cardio-Kidney Care and Trial Design' starts at 14:10. This symposium is supported by an unrestricted educational grant from AstraZeneca. This session is not intended for UK based HCPs. The main programme will begin at 15:00 CEST. #CardioEd #MedEd #KidneyDisease #CardioKidney

Traditional assessment of kidney function often relies on static eGFR values, which can miss early and clinically meaningful disease progression in cardio-kidney patients. This symposium session at New Horizons in Cardio Kidney Disease focuses on the clinical utility of eGFR slope as a dynamic marker of risk and progression. Led by an international faculty, the discussion explores how trajectory-based assessment can improve earlier identification of high-risk patients and better inform cardio-renal decision-making in practice. Register here 🔗 ow.ly/M7Bz50Ziiui This symposium is supported by an unrestricted educational grant from AstraZeneca. This session is not intended for UK based HCPs.